Skip to Content

GMO Benchmark-Free Allocation III GBMFX

Analyst rating as of
NAV / 1-Day Return
26.07  /  0.31 %
Total Assets
6.7 Bil
Adj. Expense Ratio
0.880%
Expense Ratio
0.880%
Fee Level
Average
Longest Manager Tenure
17.37 years
Category
US Fund World Allocation
Investment Style
Large Value
Credit Quality / Interest Rate Sensitivity
Status
Open
TTM Yield
3.46%
Turnover
10%
Premium

Morningstar’s Analysis

Will GBMFX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

GMO Slashes Equity Exposure After Dramatic Stock Market Runup; Ratings Unchanged

Analyst

Analyst Note

| |

GMO recently disclosed a significant allocation shift in GMO Benchmark-Free Allocation, cutting equity exposure from a 58% target weight on April 30, 2020, to a 25% target weight on May 15, 2020. The team made this cut based on its belief that the runup in developed equity markets from the March 23 bottom assumes a swift and orderly economic recovery, which the team believes is a less-than-guaranteed outcome. GMO Benchmark-Free Allocation's remaining equity exposure is concentrated in emerging-markets equities, which the team views as still significantly undervalued.

Unlock our full analysis with Morningstar Premium